Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Key Inclusion Criteria:

• Must have a diagnosis of RRMS as defined by the revised consensus definition forpediatric MS
• Must have an EDSS score between 0.0 and 5.0.
• Must have a body weight of ≥30 kg
• Must have experienced ≥1 relapse in the 12 months prior to randomization (Day 1), ormust have evidence of asymptomatic disease activity seen on MRI in the 6 months priorto randomization, or ≥2 relapses in the 24 months prior to randomization (Day 1).Relapse is defined as the occurrence of a clinical demyelination event regardless ofwhether the event is a first or subsequent demyelinating event.

Key Exclusion Criteria:

• Participants having primary progressive, secondary progressive, or progressive RMS.
• Disorders mimicking MS, such as other demyelinating disorders, systemic autoimmunedisorders, metabolic disorders, and infectious disorders.
• History of clinically significant cardiovascular, pulmonary, GI, hepatic, renal,endocrinologic, hematologic, immunologic, metabolic, dermatologic, growth,developmental, psychiatric (including depression), neurologic (other than MS), and/orother major disease and/or laboratory abnormality indicative thereof, that wouldpreclude participation in a clinical study
• Occurrence of an MS relapse within the 30 days prior to randomization (Day 1) and/orthe subject has not stabilized from a previous relapse prior to randomization NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.